Journal
CELL METABOLISM
Volume 33, Issue 7, Pages 1274-1275Publisher
CELL PRESS
DOI: 10.1016/j.cmet.2021.06.008
Keywords
-
Categories
Funding
- NIH [R01DK 117481, R01AG063404, R01AG 063389]
- National Institute of Food and Agriculture
Ask authors/readers for more resources
Numerous preclinical studies have shown a link between decreased NAD(+) signaling and metabolic disorders associated with aging and obesity. Yoshino et al. (2021) provide clinical evidence that an NAD(+) booster can enhance muscle insulin sensitivity in postmenopausal prediabetic women, highlighting the therapeutic potential of NAD(+) boosters in humans.
Numerous preclinical studies implicate the decline in NAD(+) signaling in developing aging- and obesity-associated metabolic disorders. Yoshino et al. (2021) now provide the clinical evidence that an NAD(+) booster increases muscle insulin sensitivity in postmenopausal prediabetic women, validating the therapeutic promises of NAD(+) boosters in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
